News

Currently, AG-120 is being evaluated in a Phase I clinical trial in patients with advanced hematologic malignancies that carry an IDH1 mutation. AML is characterized by rapid disease

The breakthrough therapy status is designed to expedite the development and review of medicines intended to treat serious diseases as well as help ensure patients have access to

Following the launch in the UK, the company intends to introduce Lenvima in countries across Europe. Lenvima is an orally administered molecular targeted agent which inhibits the activities

Based on achieving this critical milestone, Aspyrian Therapeutics recently submitted and has received FDA’s acceptance of an Investigational New Drug (IND) Application for RM-1929, their first-in-class, precision targeted

Epic will be responsible for sales and marketing of ELI-200, and Elite will be responsible for the manufacture of the product. Epic will pay Elite non-refundable milestone payments

Mission’s wholly-owned subsidiary, ProSolus Inc., offers unrivaled expertise in the development and manufacturing of sophisticated and convenient transdermal (through the skin) drug delivery products to treat a variety

The Company’s Phase 3 protocol provides for a 25-week study with 300 HIV-positive patients. Selection of clinical sites, IRB approvals, patients screening and other administrative matters are underway

The per share price will be based on the 20-day volume weighted average price (VWAP) of the Company’s Common Stock upon the closing of the acquisition. CBMG will

The Affordability is Access Act – legislation was introduced by US Senator Barbara Boxer along with Senator Patty Murray, Ranking Member of the Senate Health, Education, Labor, and